Pulmonary nodules in rheumatoid arthritis: the case of leflunomide
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease primarily affecting joints. Extra-articular manifestations, including pulmonary involvement, significantly contribute to morbidity and mortality. Disease-modifying antirheumatic drugs are crucial for RA treatment but may also have pulmonary side effects. The differentiation between pulmonary RA manifestations, infection in the immunosuppressed patient, and drug-induced pulmonary toxicity remains a diagnostic and therapeutic challenge. This report presents a rare case of accelerated pulmonary nodulosis associated with leflunomide therapy, emphasizing the need for careful differential diagnosis in immunosuppressed patients.
References
- Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73:1316-22. DOI: https://doi.org/10.1136/annrheumdis-2013-204627
- Tashfeen M, Jose C, Isham I, Kenneth N. The effect of disease modifying drugs on the lung in patients with rheumatoid arthritis. Southwest Respir Crit Care Chron 2016;4:3-11. DOI: https://doi.org/10.12746/swrccc2016.0413.166
- Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544-54. DOI: https://doi.org/10.1002/art.40574
- ARAVA® (leflunomide) prescribing information. Bridgewater, NJ: Sanofi-Aventis; 2010. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020905s020lbl.pdf.
- Wong SPY, Chu CM, Kan CH, et al. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol 2009;15:389-92. DOI: https://doi.org/10.1097/RHU.0b013e3181c3f87e
- Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med 2018;7:356. DOI: https://doi.org/10.3390/jcm7100356
- Lacoste-Palasset T, Chaumais MC, Weatherald J, et al. Association between Leflunomide and Pulmonary Hypertension. Ann Am Thorac Soc 2021;18:1306-15. DOI: https://doi.org/10.1183/13993003.congress-2021.OA146
- Martin N, Innes JA, Lambert CM, et al. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 2007;34:1934-7.
- Raj R, Nugent K. Leflunomide-induced interstitial lung disease: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2013;30:167-76.
- Sakai F, Noma S, Kurihara Y, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005;15:173-9. DOI: https://doi.org/10.1007/s10165-005-0387-9
- Rozin A, Yigla M, Guralnik L, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006;25:384-8. DOI: https://doi.org/10.1007/s10067-005-0024-1
- Abiyarghamsari M, Ahmadzadeh A. Pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report. Clin Case Rep 2024;13:e9615. DOI: https://doi.org/10.1002/ccr3.9615
- Karadag F, Polatli M, Senturk T, et al. Cavitary necrobiotic nodule imitating malignant lung disease in a patient without articular manifestations of rheumatoid arthritis. J Clin Rheumatol 2003;9:246-52. DOI: https://doi.org/10.1097/01.rhu.0000081260.50171.bf
- McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004;363:461. DOI: https://doi.org/10.1016/S0140-6736(04)15527-X
- Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-9. DOI: https://doi.org/10.1002/art.21806
- Braun MG, van Rhee R, Becker-Capeller D. Neuauftreten und/oder Zunahme von Rheumaknoten unter Leflunomidtherapie bei RA-Patienten. Z Rheumatol 2004;63:84-7. DOI: https://doi.org/10.1007/s00393-004-0537-z
- Grisar J. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004;63:1632-7. DOI: https://doi.org/10.1136/ard.2003.018440
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2025 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.